Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
Bank of America 2008 Healthcare Conference on May 14, 2008 at 5:20 p.m.
Pacific Time (8:20 p.m. Eastern Time) at the Four Seasons Hotel in Las Vegas,
Nevada. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief
Scientific Officer, is scheduled to provide an overview of the company,
including its clinical development and discovery programs.
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at http://www.arenapharm.com. A
replay of the presentation will be available until May 30, 2008. Please
connect to Arena's website several minutes prior to the start of the webcast
to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being
investigated in a Phase 3 clinical trial program for the treatment of obesity.
Arena's broad pipeline of novel compounds target G protein-coupled receptors,
an important class of validated drug targets, and includes compounds being
evaluated independently and with partners, including Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, internal and partnered
programs, and ability to develop compounds and commercialize drugs. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, clinical trials and studies may not proceed at the time or in the manner
Arena expects or at all, the results of clinical trials or preclinical studies
may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, the timing and receipt of payments and fees, if
any, from Arena's collaborators, and Arena's ability to redeem with common
stock any outstanding shares of its series B convertible preferred stock.
Additional factors that could cause actual results to differ materially from
those stated or implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under applicable
Contacts: Jack Lief
President and CEO
Mary Claire Duch WeissComm Partners 212.301.7228
Director, Corporate Communications
Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1682